Status:
COMPLETED
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Duchenne Muscular Dystrophy
Eligibility:
All Genders
5-10 years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of this multicentre, prospective, double blind, placebo controlled, randomized pilot study is to investigate safety and tolerance of Epigallocatechin-Gallate (EGCG, the major polyphenol in gre...
Detailed Description
Duchenne muscular dystrophy (DMD) is the most frequent neuromuscular condition to occur in childhood and youth. The course of the disease is progressive, and life expectancy is severely curtailed by t...
Eligibility Criteria
Inclusion
- Duchenne muscular dystrophy
- age 5-10 years
- ability to walk without support
- informed consent by the parents
Exclusion
- another serious organic disease
- further primary psychiatric or neurological diseases
- long-term intake of liver-toxic medicines
Key Trial Info
Start Date :
December 30 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 6 2018
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01183767
Start Date
December 30 2010
End Date
September 6 2018
Last Update
July 29 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité University Berlin
Berlin, Germany, 10405
2
DRK Kliniken Berlin, Westend, Pädiatrie
Berlin, Germany, 14050
3
Diakonisches Werk Oldenburg SPZ
Oldenburg, Germany